YolTech Therapeutics
YolTech Therapeutics Raises $45M in Series B to Advance In Vivo Gene Editing Pipeline Toward Phase 3
YolTech Therapeutics has raised $45M in Series B funding to advance its in vivo CRISPR therapies. Lead candidate YOLT-101, for familial hypercholesterolemia, shows strong LDL-C reduction in early trials, with a Phase 3 study on the horizon—a milestone for Chinese gene editing.